NeoPharm CO., LTD. (KOSDAQ:092730)

Market Cap	294.37B
Revenue (ttm)	122.41B
Net Income (ttm)	24.09B
Shares Out	15.64M
EPS (ttm)	1,540.00
PE Ratio	12.22
Forward PE	n/a
Dividend	600.00 (3.18%)
Ex-Dividend Date	Dec 27, 2024

Volume	220,867
Average Volume	365,217
Open	18,870
Previous Close	18,870
Day's Range	18,450 - 19,120
52-Week Range	10,075 - 23,000
Beta	0.66
RSI	61.71
Earnings Date	Aug 13, 2025

About MorphoSys AG

NeoPharm CO., LTD. engages in the manufacturing and sale of skin care products in South Korea. The company provides Atopalm, a non-steroid product for sensitive and dry skin; skin dermo-cosmetic products under the Real Barrier brand name; sensitive, dry, oily, or trouble-prone skin care products under the ZEROID brand; body moisturizers under the Derma-B brand name; sport care products under the MISSION ATHELETCARE brand; and dermArtlogy, a 1:1 consulting cosmetic brand. NeoPharm CO., LTD. was founded in 2000 and is headquartered in Daejeon, So...

• Industry: Household & Personal Products
• Sector: Consumer Staples
• Founded: 2000
• Employees: 172
• Stock Exchange: KOSDAQ
• Ticker Symbol: 092730

Financial Performance

In 2024, NeoPharm CO., LTD.'s revenue was 119.01 billion, an increase of 22.56% compared to the previous year's 97.10 billion. Earnings were 23.06 billion, a decrease of -0.64%.